Altimmune Announces IND Clearance for a Phase 2 Trial of HepTcell Immunotherapeutic for the Treatment of Chronic Hepatitis B

Monday, June 22, 2020 1 min read

Key Takeaway: Altimmune Announces IND Clearance for a Phase 2 Trial of HepTcell Immunotherapeutic for the Treatment of Chronic Hepatitis B

Full Press Release Details

Altimmune Announces IND Clearance for a Phase 2 Trial of HepTcell Immunotherapeutic for the Treatment of Chronic Hepatitis B.